CCM
GBT

Cribstone Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Cribstone Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,328
Closed -$56K – 764
2016
Q4 		$56K Buy
3,328
+4
+0.1% +$70 0.03% 249
2016
Q3 		$60K Buy
+3,324
New +$63.4K 0.04% 241

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WSC
White Square Capital London, United Kingdom $14.7M AUM 151.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Cribstone Capital Management's GBT Position: Q1 2017 in Review

Cribstone Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2017, closing a stake of 3,328 shares — an estimated $56K sold.

Cribstone Capital Management first reported a position in GBT in Q3 2016 and held it in 2 quarters. The position peaked at $60K in Q3 2016. 116 funds tracked by Wall St. Rank hold GBT as of Q1 2017.

  • Cribstone Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Cribstone Capital Management sold 3,328 Global Blood Therapeutics, Inc. shares in Q1 2017, an estimated $56K.
  • Cribstone Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • Cribstone Capital Management's Global Blood Therapeutics, Inc. position peaked at $60K in Q3 2016.
  • 116 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2017.

Based on Cribstone Capital Management's 13F filing for Q1 2017, filed 17 Apr 2017.